br Olfat G Shaker Mahmoud A Senousy br Supplemental

Olfat G. Shaker, Mahmoud A. Senousy
Supplemental Table 2 Hardy-Weinberg Equilibrium for 6 SNPs in Patients With BC and in Control Subjects
SNP No.
Observed Frequencies
Expected Frequencies
P
TC
CC TT
TC
CC
GC
CC GG
GC
CC
TC
CC TT
TC
CC
CG
GG CC
CG
GG
CT
CC TT
CT
CC
AG
AA GG
AG
AA
Abbreviations: BC ¼ breast cancer; CHI3L1 ¼ chitinase-3elike protein 1; OPG ¼ osteoprotegerin; RANKL ¼ receptor activator of nuclear factor kB ligand; VDR ¼ vitamin D receptor.
SNP-SNP Interactions
Supplemental Table 3 Genotype Association of Studied SNPs With Breast Cancer Risk
Control
Adjusted OR Pa
Log additive —
Log additive —
Log additive —
Log additive —
Olfat G. Shaker, Mahmoud A. Senousy
Supplemental Table 3 Continued
Control
Adjusted OR Pa
SNP Model
Dominant
Recessive
Overdominant
Log additive
Codominant
Dominant
Recessive
Overdominant
Log additive
Abbreviations: AIC ¼ Akaike-information-criterion; BIC ¼ Bayesian-information-criterion; CHI3L1 ¼ chitinase-3elike protein 1; CI ¼ confidence interval; OPG ¼ osteoprotegerin; OR ¼ odds ratio; RANKL ¼ receptor activator of nuclear factor kB ligand; SNP ¼ single nucleotide polymorphism; VDR ¼ vitamin D receptor. aAdjusted for age and family history in logistic regression model. Statistically significant.
SNP-SNP Interactions
Abbreviations: LD ¼ 9026-93-1 disequilibrium; OPG ¼ osteoprotegerin; RANKL ¼ receptor activator of nuclear factor kB ligand; SNP ¼ single nucleotide polymorphism; VDR ¼ vitamin D receptor.
Available online at www.sciencedirect.com
Respiratory Investigation
Original article
Association of specific metastatic organs with the prognosis and chemotherapeutic response in patients with advanced lung cancer
Nobuhiro Kanaji*, Akira Tadokoro, Naoki Watanabe, Takuya Inoue, Norimitsu Kadowaki, Tomoya Ishii
Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan
Article history:
Received in revised form
Available online xxx
Keywords:
Metastasis
Organ
Response rate
Prognosis
Lung cancer
Background: This study was performed to investigate the influence of specific metastatic organs on the prognosis and therapeutic effect in patients with advanced lung cancer. Methods: We retrospectively analyzed 400 patients with pathologically diagnosed advanced lung cancer to determine the association of the patients’ metastatic status with their prognoses and responses to first-line therapy. Metastases within the chest cavity (pul-monary metastasis, pleural effusion, and pericardial effusion) were counted as one organ. Results: The numbers of metastatic organs in the patients were as follows: one (n¼199 patients), two (n¼99), three (n ¼61), and four or more (n¼41). A multivariate analysis showed that liver and muscle metastases were independently associated with shorter overall survival (median of 207 and 120 days, respectively) and shorter progression-free survival (median of 125 and 53 days, respectively). Chest cavity, bone, brain, and lymph node metastases were not associated with survival. The presence of either muscle or skin metastasis was associated with a lower response rate to first-line therapy than was the absence of each metastasis (14.3% vs. 49.4% and 11.1% vs. 48.9% in patients with vs. without muscle or skin metastasis, respectively).
Conclusions: Muscle and liver metastases were associated with poor outcomes. Muscle and skin metastases were associated with a lower response rate to treatment. For patients with advanced lung cancer, oncologists should select treatment strategies considering the pa-tients’ metastatic statuses as well as other clinical characteristics.
© 2019 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.
Abbreviations: CT, computed tomography; EGFR, epidermal growth factor receptor; EPMS, extrapulmonary metastatic site; 18F-FDG, 18F-2-fluoro-2-deoxy-D-glucose; HGF, hepatocyte growth factor; ILD, interstitial lung disease; NSCLC, non-small cell lung cancer; OS, overall survival; PET, positron emission tomography; PFS, progression-free survival; SCLC, small cell lung cancer; TKI, tyrosine kinase inhibitor.